Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK

Noradrenaline for progressive supranuclear palsy syndromes (NORAPS): a randomised, double-blind, placebo-controlled, crossover Phase IIb clinical trial evaluating the efficacy and safety of oral atomoxetine for treating cognitive and behavioural changes in people with progressive supranuclear palsy syndromes in the UK

Introduction Progressive supranuclear palsy (PSP) is a devastating neurodegenerative disease characterised by cognitive, behavioural and motor problems. Motor symptoms are highly disabling, while cognitive and behavioural changes have a major impact on carer burden, quality of life and prognosis. Ap...

Full description

Saved in:
Bibliographic Details
Main Authors: Robert Durcan, Christopher Kobylecki, Lee Shepstone, James B Rowe, Alistair Church, Duncan Street, Vicky Marshall, Charlotte Russell, Luca Passamonti, Juliet High, Christopher T Rodgers, Boyd C P Ghosh, Kelly Grant, Natalia Igosheva, Hugo Paula, Colin McAlister, Simon P Jones, Rong Ye, Chrystalina Antoniades
Format: Article
Language:English
Published: BMJ Publishing Group 2025-07-01
Series:BMJ Open
Online Access:https://bmjopen.bmj.com/content/15/7/e099577.full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://bmjopen.bmj.com/content/15/7/e099577.full

Similar Items